Compare JF & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JF | HSCS |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | China | United States |
| Employees | 30 | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 15.8M |
| IPO Year | 2017 | 2022 |
| Metric | JF | HSCS |
|---|---|---|
| Price | $0.91 | $4.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 7.8K | ★ 136.2K |
| Earning Date | 04-24-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,319.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.81 | $1.63 |
| 52 Week High | $1.19 | $5.25 |
| Indicator | JF | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 38.44 | 54.15 |
| Support Level | $0.90 | $1.88 |
| Resistance Level | $1.03 | $4.35 |
| Average True Range (ATR) | 0.05 | 0.52 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 0.00 | 42.50 |
J and Friends Holdings Ltd providing merchant digitalization and commerce-enablement solutions to small and medium enterprises (SME). Its solutions feature critical functionality that SMEs need to engage with consumers, manage their operations, accept payments, and grow their business. Such solutions empower single- and multi-location retailers, restaurants, and other SMEs to compete successfully in an omni-channel market environment by engaging with consumers across online, mobile, and physical channels. The group conducts all of its current operations in Australia and generates revenues from continuing operations are derived from within Australia.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.